Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Journey Medical (DERM) Equity Average: 2020-2025

Historic Equity Average for Journey Medical (DERM) over the last 4 years, with Sep 2025 value amounting to $22.6 million.

  • Journey Medical's Equity Average rose 103.16% to $22.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.6 million, marking a year-over-year increase of 103.16%. This contributed to the annual value of $20.2 million for FY2024, which is 8.27% up from last year.
  • Per Journey Medical's latest filing, its Equity Average stood at $22.6 million for Q3 2025, which was up 10.68% from $20.4 million recorded in Q2 2025.
  • Journey Medical's Equity Average's 5-year high stood at $41.7 million during Q1 2022, with a 5-year trough of $3.7 million in Q2 2023.
  • For the 3-year period, Journey Medical's Equity Average averaged around $14.8 million, with its median value being $15.5 million (2024).
  • As far as peak fluctuations go, Journey Medical's Equity Average tumbled by 90.17% in 2023, and later spiked by 223.41% in 2024.
  • Quarterly analysis of 5 years shows Journey Medical's Equity Average stood at $15.2 million in 2021, then skyrocketed by 42.30% to $21.6 million in 2022, then declined by 12.61% to $18.9 million in 2023, then dropped by 17.84% to $15.5 million in 2024, then spiked by 103.16% to $22.6 million in 2025.
  • Its Equity Average was $22.6 million in Q3 2025, compared to $20.4 million in Q2 2025 and $20.8 million in Q1 2025.